Please assess the completion status of the following clinical trial:

Trial Title: 68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Known prostate cancer~* Planned HIFU or HDR local therapy~* Able to provide written consent~* Karnofsky performance status of 50 (or Eastern Cooperative Oncology Group (ECOG) /World Health Organization (WHO) equivalent)~Exclusion Criteria:~* Patients not capable of getting PET study due to weight, claustrophobia, or inability to lay still for the duration of the exam~* Metallic implants (contraindicated for MRI)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 68-Ga RM2+68-Ga PSMA11 (Type: EXPERIMENTAL): 68-Ga RM2 first followed by 68-Ga PSMA11 within 2 weeks. Participant will be injected IV with 140 ± 20% mBq of 68-Ga RM2 OR 3 to 7 mCi of 68-Ga PSMA11
- 68-Ga PSMA11+68-Ga RM2 (Type: EXPERIMENTAL): 68-Ga PSMA11 first followed by 68-Ga RM2 within 2 weeks. Participant will be injected IV with 140 ± 20% mBq of 68-Ga RM2 OR 3 to 7 mCi of 68-Ga PSMA11

Based on this trial design, predict the completion outcome and termination type (if applicable).